Big Buttons

• Full of sound and fury, signifying nothing

  Novo Nordisk tried to convince the FDA that semaglutide injections are difficult to compound. (Spoiler: They aren't.) read more →

• Video: APC on Scripps

  APC CEO Scott Brunner appeared on the Scripps News show “America On The Docket,” talking about the “brewing legal battle” over compounded tirzepatide and semaglutide. read more →

• BREAKING: FDA allows renewed compounding of tirzepatide copies — for now

  In a win for continued patient access to compounded versions of Eli Lilly’s Mounjaro and Zepbound, FDA clarified today that pharmacies may continue to prepare copies of those FDA-approved drugs, at least for now. read more →

• FDA issues IV fluids emergency guidance

  The FDA has published emergency guidance that empowers pharmacies to help address the nationwide IV solutions shortage. read more →

• Welcome aboard, GYMA

  It's our newest tier-level corporate patron. read more →

• The Journey to Earning the CPhT-Adv Certification from PTCB

  Earning the Advanced Certified Pharmacy Technician Certification from the Pharmacy Technician Certification Board is a great way to boost your professional skills and career opportunities. read more →

• Technicians: Professional Development through Mentorship

  Mentors play a crucial role in career advancement by offering guidance, encouragement, advocacy, and networking potential. Identifying the right mentor within your industry is essential. read more →

• FDA reconsiders on tirzepatide, big questions remain

  After a court order, the FDA agreed to reconsider taking tirzepatide off the shortage list. read more →

More News

The Hill covers the fallout from the FDA’s taking tirzepatide off the shortage list — especially how compounders are pushing back — in “Rivals fight for right to sell weight loss drugs.” Of course it quotes APC:

Scott Brunner, CEO of the Alliance for Pharmacy Compounding, said in a press briefing that “a lot of patients have been left flat footed” by the FDA ending the shortage.